Arwr stock zacks
Arrowhead Pharmaceuticals, Inc. (ARWR) Dividend Date & ... See the upcoming ex dividend date and dividend history for Arrowhead Pharmaceuticals, Inc. (ARWR). Stay alerted to dividend announcements for … Arrowhead Pharma up 5% after Medicines Co. sale ... Nov 25, 2019 · Baird upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to Outperform with $70 price target (40% upside), noting Novartis' purchase of The Medicines Company means a re-evaluation of ARWR's RNAi platfo ARWR - Arrowhead Pharma Stock Price - Barchart.com For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more. Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. It is computed by multiplying the market price by the number of outstanding shares. ARWR - Arrowhead Pharmaceuticals Inc Stock quote ...
View detailed financial information, real-time news, videos, quotes and analysis on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR). Explore commentary on Arrowhead Pharmaceuticals Inc. and hear what
ARWR Description — Arrowhead Pharmaceuticals Inc. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. Finance - Zacks The Zacks Personal Finance Channel provides guidance about investing, insurance, retirement planning and taxes so readers can make informed decisions about their financial futures. ARWR -- Is Its Stock Price A Worthy Investment? Learn More. ARWR Stock Summary. ARWR's price/sales ratio is 16.75; that's higher than the P/S ratio of 94.22% of US stocks. Over the past twelve months, ARWR has reported earnings growth of -245.54%, putting it ahead of merely 6.04% of US stocks in our set.
LifeSci Capital. Patrick Dolezal. Piper Jaffray. Ted Tenthoff. Zacks. Brian Marckx $26.91 +0.39 (0.00%) NASDAQ (ARWR) 4:00 PM EDT - 04.02.20. Copyright
Mar 20, 2020 · Find the latest Earnings Report Date for Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) at Nasdaq.com. Looking for additional market data? According to Zacks Investment Research, based on Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis ... Get breaking news and analysis on Arrowhead Pharmaceuticals, Inc. (ARWR) stock, price quote and chart, trading and investing tools. ARWR Stock Price | Arrowhead Pharmaceuticals Corp. Stock ...
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 4 cents per share. The drug developer posted revenue of $29.5 million in the period, which also did not meet Street forecasts. Four analysts surveyed by Zacks expected $36.6 million.
Zacks Small Cap Research - ARWR: Arrowhead Acquires ... By Grant Zeng, CFA. NASDAQ:ARWR. Earlier today (March 5), Arrowhead (NASDAQ:ARWR) announced the acquisition of Novartis’ entire RNAi research and development portfolio and associated assets.. The Deal. The acquisition includes: · Multiple patent families covering RNAi-trigger design rules and modifications that fall outside of key patents controlled by … Arrowhead Pharmaceuticals Inc. ARWR - Quotes, Financials ...
17 Oct 2019 TheTechTrader.com Arrowhead Pharmaceuticals, Inc. (ARWR), an old swing traded of This stock may pop up through and take out 27.60, which could lead to 31-32, and then 35. Zacks Investment Research 870 views.
Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) Real ... ARWR's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. NLS Volume "Volume" is the number of shares of the stock traded on the listing exchange during regular trading hours. Previous Close Today's High … ARWR Arrowhead Pharmaceuticals, Inc. Stock Quote Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat Zacks 58 | ARWR Message Board Posts
Arrowhead Pharmaceuticals, Inc. Message board - Online Community of active, educated investors researching and discussing Arrowhead Pharmaceuticals, Inc. Stocks. Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Arrowhead Pharmaceuticals, Inc. ARWR is scheduled to release first-quarter fiscal 2020 results on Feb 5, after market close. The company missed earnings estimates in three of the trailing four quarters by 33.37%, on average. In the last reported quarter, Arrowhead came up with a negative earnings surprise of 21.43%. Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?